Crossmark

Long-term outcomes of blue light laser therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia within a multimodal treatment concept

Crossref DOI link: https://doi.org/10.1007/s00405-025-09919-3

Published Online: 2026-01-20

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Heiß, Christina https://orcid.org/0009-0005-0615-4195
Bohr, Christopher https://orcid.org/0000-0003-0921-7436
Kühnel, Thomas S. https://orcid.org/0000-0001-6660-1130
Müller, Karolina https://orcid.org/0000-0001-5241-2945
Zeman, Florian https://orcid.org/0000-0002-8425-984X
Andorfer, Kornelia E. C. https://orcid.org/0000-0002-5195-0634
Funding

Funding for this research was provided by:

Universitätsklinikum Regensburg
License Information

Text and Data Mining valid from 2026-01-20

Version of Record valid from 2026-01-20
More Information

Article History

Received: 2 April 2025

Accepted: 7 November 2025

First Online: 20 January 2026

Declarations

:

: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the University of Regensburg (Approval number: 25-4054-104, Approval date: 21 January 2025). .

: The authors declare that no conflict of interest exists.

Document is current

Any future updates will be listed below